In addition, a recent clinical trial reported that while 73% of patients with relapsed BL-ALL achieve complete remission after higher dose levels of CD22CAR T-cells, those who relapse do so with CD22(−) or -dim disease [16]. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.